Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis by Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

Subjects: Get full text

Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report by Yoshitaka Saito, Yoh Takekuma, Hajime Asahina, Ryo Hisada, Mitsuru Sugawara

“…A man in his sixties received atezolizumab monotherapy as the sixth-line treatment. …”
Get full text

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy by Tian He, Bin Xu, Lu-Na Wang, Zi-Yi Wang, Huan-Chen Shi, Cheng-Jie Zhong, Xiao-Dong Zhu, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun, Bo Hu, Cheng Huang

Subjects: Get full text

Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study by Hannelore Denys, Frederik Marmé, Frederic Forget, Lukas Rob, Pawel Blecharz, Kristina Lindemann, Peter Hillemanns, Linn Wölber, Theresa Link, Jean-Francois Baurain, Mariusz Bidziński, Linn Woelber, Michal ZikÁN, Josef Chovanec, Christian Dannecker, Stéphanie Henry, Hannelore G Denys, Velko Minchev, Anders Rosholm, Kaja C G Berg, Roberto S Oliveri, Marchela Koleva, Bozhil Robev

“…Patients received 3 mg VB10.16 (every 3 weeks (Q3W) for 12 weeks, hereafter every 6 weeks) combined with 1,200 mg atezolizumab (Q3W) for 48 weeks in total with a 12-month follow-up. …”
Get full text

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence by Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata

Subjects: “…atezolizumab…”
Get full text

Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging by Linhan Zhang MD, Lianmeng Zhao MS, Xue Lin MD, Sheng Zhao MD, Wenbin Pan MS, Dandan Wang MD, Zhongqi Sun MD, Jinping Li MD, Zonghui Liang MD, Rongjun Zhang MS, Huijie Jiang MD

“…TTU were observed by 131 I-labeled Atezolizumab and IgG in-vitro distribution. Results Labeled IgG concentrated more in tumors than Atezolizumab. …”
Get full text

Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy by Jie Yang, Jian-Guo Zhou, Benjamin Frey, Hu Ma, Haitao Wang, Markus Hecht, Rainer Fietkau, Udo Gaipl, Xiaofei Chen, Ada Hang-Heng Wong, Fangya Tan, Si-Si He, Gang Shen, Yun-Jia Wang, Wenzhao Zhong

“…We aimed to develop a predictive framework based on machine learning (ML) methods to identify FP in advanced NSCLC patients using blood test biomarkers.Methods and analysis We extracted data of 1546 atezolizumab-treated patients from four multicentre clinical trials. …”
Get full text

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors by Ernest Choy, Yohann Loriot, Fabio Calabrò, Cora N Sternberg, Guillermo De Velasco, Daniel Castellano, Roubini Zakopoulou, Aristotelis Bamias, Nicholas James, Axel Merseburger, F Lopez-Rios, Mario Kramer, Kimon Tzannis

“…Our aim was to develop an improved prognostic model in patients receiving second-line atezolizumab for aUC.Methods Patients with aUC progressing after cisplatin/carboplatin-based chemotherapy and enrolled in the prospective, single-arm, phase IIIb SAUL study were included in this analysis. …”
Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA... by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

“…Results We analyzed 13,580 reports of AEs associated with five ICIs, namely, durvalumab, pembrolizumab, ipilimumab, atezolizumab, and nivolumab from January 2013 to October 2022. …”
Get full text

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature by Ioanna Tsiouprou, Athanasios Zaharias, Dionisios Spyratos

“…Nowadays, evidence show a statistically significant survival benefit of adding atezolizumab, an IgG1 monoclonal antibody targeting against PD-L1, to platinum-based chemotherapy plus etoposide in patients who have not received any previous systemic therapy. …”
Get full text

Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer by Beatriz Ramos, Dakota Rogers

“…Immune checkpoint inhibitors such as nivolumab, pembrolizumab, avelumab, and atezolizumab have shown promising results in clinical trials and have been approved for metastatic and high-risk bladder cancer. …”
Get full text

Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports by Alessandro Ceschi, Roberta Noseda, Raffaela Bertoli, Laura Müller

“…We retrieved the individual case safety reports reporting HLH in association with ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab or durvalumab, gathered in the database starting from the ICIs’ approval dates by the US Food and Drug Administration. …”
Get full text

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study by Laura Moliner, MD, Núria Zellweger, MSc, Sabine Schmid, MD, Martina Bertschinger, MD, Christine Waibel, MD, Ferdinando Cerciello, MD, PhD, Patrizia Froesch, MD, Michael Mark, MD, Adrienne Bettini, MD, Pirmin Häuptle, MD, Veronika Blum, MD, Lisa Holer, MSc, Stefanie Hayoz, PhD, Martin Früh, MD, Samreen Ahmed, FRCP, MD, MBBS, MSc, Shradha Bhagani, MD, Nicola Steele, MD, Hannah-Leigh Gray, BSc, Stephen D. Robinson, MD, Michael Davidson, MD (Res), Samantha Cox, MD, MSc, MBBCh, Taha Khalid, MD, Tom R. Geldart, MD, Luke Nolan, FRCS, PhD, Deborah C. Scott, MBChB (MRCP), Lindsay Hennah, MD, Tom Newsom-Davis, MD, PhD, Emma Rathbone, MD, PhD, Catherine Handforth, MD, Arshi Denton, MD, Shairoz Merchant, PhD, Fiona Blackhall, MD, PhD, Laetitia A. Mauti, MD, Raffaele Califano, MD, Sacha I. Rothschild, MD, PhD

“…Patients received platinum-etoposide chemotherapy in combination with immunotherapy (atezolizumab or durvalumab). Patient, tumor, and treatment details were collected. …”
Get full text

Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients by Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto

“…Endocrine-related irAE (E-irAE), other irAE (O-irAE), endocrine-related and other irAE (EO-irAE), and multiple endocrine-related irAE (ME-irAE) were evaluated in groups. 80.8% of patients had an irAE, with the highest incidence of irAE with ipilimumab plus PD-1 inhibitor, followed by atezolizumab 59.0%, pembrolizumab 53.7%, avelumab 50.0%, and nivolumab 47.3%, Durvamumab 26.7% followed; Kaplan-Meier survival curves showed higher survival rates in patients with irAE compared to non-irAE, and higher survival rates in EO-irAE and ME-irAE compared to E-irAE and O-irAE (p < 0.001). …”
Get full text

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer by Jie Fu, Jie Fu, Yi-Dan Yan, Xu Wan, Xiao-Fan Sun, Xiao-Fan Sun, Xiu-Mei Ma, Ying-Jie Su

“…Compared with chemotherapy, monotherapy with nivolumab, cemiplimab, pembrolizumab, atezolizumab and durvalumab had lower odds of TRAE grade ≥3.ConclusionIn all patients, penpulimab plus chemotherapy was the most effective therapy, but treatment preferences varied by PD-L1 expression, histology type and associated outcomes. …”
Get full text

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer by Soomin Kim, Jaemoon Koh, Tae Min Kim, Songji Oh, Soyeon Kim, Jeonghwan Youk, Miso Kim, Bhumsuk Keam, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo

“…Two patients who showed the opposite pattern, transiting from C4 to C2, had durable responses to subsequent atezolizumab/bevacizumab/carboplatin/paclitaxel treatment. …”
Get full text

Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial by Łukasz Kuncman, Jacek Fijuth, Damian Tworek, Ewa Sierko, Paweł Cisek, Michał Masłowski, Maja Lisik-Habib, Magdalena Orzechowska, Katarzyna Galwas-Kliber, Adam Antczak, Izabela Chmielewska, Barbara Ziółkowska, Marta Kurczewska-Michalak, Wojciech Kuźnicki, Nina Jędrzejczak, Kinga Ranoszek, Mateusz Bilski

“…. • Arm I will serve as the control group, comprising patients who continue SoC of programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) immunotherapy (durvalumab or atezolizumab) following platinum-based chemo-immunotherapy. • Arm II will receive the SoC with consolidative RT to the chest area and potentially, according to palliative indications to metastatic lesions, delivered in 30 Gy in 3-Gy fractions. • Arm III will receive SoC with RT of 45 Gy in 3-Gy fractions to the chest area and stereotactic body radiotherapy (SBRT) with 24 Gy in 8-Gy fractions to the metastatic lesions. …”
Get full text

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells by Methi Wathikthinnakon, Piriya Luangwattananun, Nunghathai Sawasdee, Chutipa Chiawpanit, Vannajan Sanghiran Lee, Piyarat Nimmanpipug, Yingmanee Tragoolpua, Siriphorn Rotarayanont, Thanich Sangsuwannukul, Nattaporn Phanthaphol, Yupanun Wutti-in, Chalermchai Somboonpatarakun, Thaweesak Chieochansin, Mutita Junking, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus, Aussara Panya

“…Two recombinant PD-L1xCD3 BiTEs (mBiTE and sBiTE contain anti-PD-L1 scFv region from atezolizumab and from a published sequence, respectively) were able to specifically bind to both CD3 on T lymphocytes, and to PD-L1 overexpressed after gemcitabine treatment on CCA (KKU213A, KKU055, and KKU100) cells. mBiTE and sBiTE significantly enhanced T lymphocyte cytotoxicity against CCA cells, especially after gemcitabine treatment, and their magnitudes of cytotoxicity were positively associated with the levels of PD-L1 expression. …”
Get full text